This guideline covers diagnosing and managing bladder cancer in people 18 and above referred from primary care with suspected bladder cancer, and those with newly diagnosed or recurrent bladder (urothelial carcinoma, adenocarcinoma, squamous-cell carcinoma or small-cell carcinoma) or urethral cancer.
effective and cost effective for people using secondary care services, including women who are pregnant or have recently given birth?...
licensed nicotine-containing products) to level of smoking addiction among women who are using maternity services? Any explanatory...
Everything NICE has said on assessing and managing renal and ureteric stones in children, young people and adults in an interactive flowchart.
Everything NICE has said on preventing, detecting and managing acute kidney injury in an interactive flowchart
of early pregnancy assessment units in improving physical and emotional health compared with services provided outside of a dedicated...
Advice on the use of the AliveCor Heart Monitor and AliveECG (Kardia Mobile) app for detecting atrial fibrillation (AF) to aid local decision-making
Summary of the evidence on telavancin (Vibativ) for hospital-acquired pneumonia caused by MRSA to inform local NHS planning and decision-making
Evidence-based recommendations on faecal calprotectin diagnostic tests for inflammatory diseases of the bowel
Everything NICE has said on chronic kidney disease (renal failure) in an interactive flowchart
This guideline covers the diagnosis and management of type 1 and type 2 diabetes in children and young people aged under 18. The guideline recommends strict targets for blood glucose control to reduce the long-term risks associated with diabetes.
This guideline covers the care and treatment of adults (aged 18 and over) with type 1 diabetes.
How NICE recommendations are being used to improve outcomes for people with diabetes
Advice on the use of the Somatom Definition Edge CT scanner for imaging coronary artery disease to aid local decision-making
Advice on the use of the Aquilion PRIME CT scanner for imaging coronary artery disease to aid local decision-making
This guideline covers the assessment and early management of spinal column and spinal cord injury in pre-hospital settings (including ambulance services), emergency departments and major trauma centres. It covers traumatic injuries to the spine but does not cover spinal injury caused by a disease.It aims to reduce death and disability by improving the quality of emergency and urgent care.
Advice on the use of the TearLab osmolarity system for diagnosing dry eye disease to aid local decision-making
This guideline covers the recognition, diagnosis and early management of sepsis for all populations. The guideline committee identified that the key issues to be included were: recognition and early assessment, diagnostic and prognostic value of blood markers for sepsis, initial treatment, escalating care, identifying the source of infection, early monitoring, information and support for patients and carers, and training and education.
This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.
The NICE public health guidance development process (third edition)
Advice on the use of the LARS (ligament augmentation and reconstruction system) for reconstructing damaged intra-articular cruciate knee ligaments...
Everything NICE has said on assessing, diagnosing, treating and reducing the risk of venous thromboembolism in adults in an interactive flowchart
This guideline covers diagnosing and managing spondyloarthritis that is suspected or confirmed in adults who are 16 years or older. It aims to raise awareness of the features of spondyloarthritis and provide clear advice on what action to take when people with signs and symptoms first present in healthcare settings. It also provides advice on the range of treatments available.
How NICE recommendations are helping to improve the prevention of cardiovascular disease
Methods for the development of NICE public health guidance (third edition)
receive a quality of life (QALY) gain equivalent to around 30 days perfect health with THC:CBD spray added to standard care. The...
Everything NICE has said on antibiotic prescribing for self-limiting respiratory tract and ear infections in primary care in an interactive flowchart
In development [GID-TA10261] Expected publication date: TBC
Everything NICE has said on the recognition, diagnosis and early management of sepsis in an interactive flowchart
This guideline covers the care and management of type 2 diabetes in adults (aged 18 and over). It focuses on patient education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.
Developing NICE guidelines: the manual
Advice on the use of TheraSphere for treating operable and inoperable hepatocellular carcinoma (liver cancer) to aid local decision-making
In development [GID-TAG387] Expected publication date: TBC
Interim methods guide for developing good practice guidance
The social care guidance manual
Clinician Cervical Ripening Ballon for the Induction of Labour in Pregnant Women GYNAECOLOGY, PREGNANCY AND BIRTH Minor modification of...
Advice on the use of the Alair bronchial thermoplasty system for treating adults with severe, difficult to control asthma to aid local decision-making
This guideline covers assessing and managing motor neurone disease (MND). It aims to improve care from the time of diagnosis, and covers information and support, organisation of care, managing symptoms and preparing for end of life care.
In development [GID-DT14] Expected publication date: TBC
This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow-up in primary care for people diagnosed with prostate cancer.
This information helps ministers to decide whether or not a technology should be formally referred to NICE for appraisal and whether it should be referred as an MTA or an STA.
An ovarian cancer treatment, designed to help maintain the effects of chemotherapy, has been approved by NICE for use in the Cancer Drugs Fund (CDF).
Draft guidance published today (3 October 2019) by NICE does not recommend atezolizumab (also called Tecentriq and made by Roche) for treating people with a type of breast cancer called triple A breast cancer that has spread to other parts of the body and who can’t have surgery to remove it.
Regularly monitoring women who are pregnant with twins or triplets, to spot any possible complications, can lead to better outcomes for mothers and their babies, as highlighted in NICE’s impact report.
NICE has today (7 August 2019) published draft guidance recommending neratinib as an additional treatment for some people with early hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
Olaparib, a medicine that has previously been used at a later stage in the treatment of advanced ovarian cancer, has now been approved by NICE as a first-line maintenance treatment.
Another potentially life-extending drug combination for some people with advanced breast cancer will now be available on the Cancer Drugs Fund (CDF) following its approval by NICE in draft guidance published today (17 July 2019).
NICE has urged local authorities and the public to be aware of the air quality in their homes and to reduce their exposure to indoor pollutants.
Shared Learning Award 2019 finalist
NICE has today (28 August 2019) published its updated guideline on the diagnosis and treatment of high blood pressure (hypertension).